3-(2,4-dimethoxybenzylidene)anabaseine has been researched along with piperidines in 2 studies
Studies (3-(2,4-dimethoxybenzylidene)anabaseine) | Trials (3-(2,4-dimethoxybenzylidene)anabaseine) | Recent Studies (post-2010) (3-(2,4-dimethoxybenzylidene)anabaseine) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
---|---|---|---|---|---|
166 | 8 | 81 | 40,235 | 5,221 | 14,545 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cannon, CE; Eddins, D; Egbertson, MS; Puri, V; Uslaner, JM; Vivian, JA | 1 |
Gromov, MS; Maslyakov, VV; Zabrodskii, PF | 1 |
2 other study(ies) available for 3-(2,4-dimethoxybenzylidene)anabaseine and piperidines
Article | Year |
---|---|
The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Behavior, Animal; Benzylidene Compounds; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Donepezil; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Indans; Ketamine; Macaca mulatta; Male; Molecular Targeted Therapy; Nicotinic Agonists; Nootropic Agents; Piperidines; Psychomotor Performance; Pyridines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Schizophrenia | 2013 |
Combined Effects of M1 Muscarinic Acetylcholine Receptor Agonist TBPB and α7n-Acetylcholine Receptor Activator GTS-21 on Mouse Mortality and Blood Concentration of Proinflammatory Cytokines in Sepsis.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzimidazoles; Benzylidene Compounds; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Gene Expression Regulation; Interleukin-1beta; Interleukin-6; Male; Mice; Muscarinic Agonists; Nicotinic Agonists; Piperidines; Pyridines; Receptor, Muscarinic M1; Sepsis; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |